Join our daily newsletter At The Bell to receive exclusive market insights
- Noxopharm (NOX) is set to progress to part two of its clinical trial of drug candidate Veyonda to treat prostate cancer
- Safety data from the company’s third cohort of patients in its DARRT-2 trial was reviewed by the Safety Steering Committee, following a dose escalation
- The third cohort of patients in the study were treated with a 1600-milligram dose of Veyonda which was found to be safe, resulting in a halt to further dose escalations
- The trial now has the green light to progress to part two, which will evaluate efficacy signals while safety data continues to be collected before Q2 2023
- Noxopharm are trading steady at 13.5 cents at 10:34 am AEDT
Noxopharm (NOX) is set to progress to part two of its clinical trial of its drug candidate Veyonda to treat prostate cancer.
Safety data from the company’s third cohort of patients in its DARRT-2 trial was reviewed by the Safety Steering Committee, following a dose escalation.
The DARRT-2 trial is evaluating Veyonda in combination with low-dose external beam radiotherapy to treat prostate cancer, along with breast and lung cancer patients on an exploratory basis.
Most recently, the third cohort of patients in the study were treated with a 1600-milligram dose of Veyonda, which was found to be safe.
This means no further dose escalations will occur and the trial has the green light to progress to part two, which will evaluate efficacy signals while safety data continues to be collected.
“We are proceeding according to schedule as we now wind down the first part of the trial and look to start focusing on efficacy in the very near future,” Noxopharm CEO Dr Gisela Mautner said.
“As stated in the recent AGM, we are actively exploring ways to reduce patient numbers and costs while bringing forward efficacy data.
“And when results are meaningful, we will target data releases via high-profile conferences and peer-reviewed publications to maximise commercial potential.”
Pending protocol requirements, part two is expected to launch before early in Q2 2023.
Noxopharm were trading steady at 13.5 cents at 10:34 am AEDT.
